Use of HDGF antibody therapy has significantly increased the antineoplastic activity of gemcitabine, bevacizumab, and chemotherapy in non-small cell lung cancer (Ren et al., 2009; Zhao et al., 2013). This evidence concerns the gene HDGF and non-small cell lung carcinoma.